Bayforest Capital LTD Apellis Pharmaceuticals, Inc. Transaction History
Bayforest Capital LTD
- $79.8 Billion
- Q4 2024
A detailed history of Bayforest Capital LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bayforest Capital LTD holds 9,839 shares of APLS stock, worth $277,263. This represents 0.39% of its overall portfolio holdings.
Number of Shares
9,839Holding current value
$277,263% of portfolio
0.39%Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
301Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$344 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$335 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$333 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$283 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$271 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.1B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...